Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.

MLA

Wellaway, Christopher R., et al. “Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-Inflammatory and Antiproliferative Phenotype.” Journal of Medicinal Chemistry, vol. 63, no. 17, Sept. 2020, pp. 9020–44. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.0c00566.

APA

Wellaway, C. R., Bamborough, P., Bernard, S. G., Chung, C.-W., Craggs, P. D., Cutler, L., Demont, E. H., Evans, J. P., Gordon, L., Karamshi, B., Lewis, A. J., Lindon, M. J., Mitchell, D. J., Rioja, I., Soden, P. E., Taylor, S., Watson, R. J., Willis, R., Woolven, J. M., … Prinjha, R. K. (2020). Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype. Journal of Medicinal Chemistry, 63(17), 9020–9044. https://doi.org/10.1021/acs.jmedchem.0c00566

Chicago

Wellaway, Christopher R, Paul Bamborough, Sharon G Bernard, Chun-Wa Chung, Peter D Craggs, Leanne Cutler, Emmanuel H Demont, et al. 2020. “Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-Inflammatory and Antiproliferative Phenotype.” Journal of Medicinal Chemistry 63 (17): 9020–44. doi:10.1021/acs.jmedchem.0c00566.